A daily dose of transdermal testosterone for 16 weeks improved sexual satisfaction.
A daily 90-µL dose of transdermal testosterone for 16 weeks modestly increased the mean number of satisfactory sexual events (SSEs)-by almost one per month-among premenopausal women with a reduced libido and a low serum-free testosterone level at baseline.
The somewhat ambiguous results come from a randomized, double-blind, placebo-controlled trial involving six Australian medical centers and 261 women aged 35 to 46 years who reported a decrease in satisfying sexual activity and who had a morning serum-free testosterone level less than 3.8 pmol/L (<1.1 pg/mL).
One smaller and one larger dose of transdermal testosterone were also tested that yielded results similar to that found with placebo, indicating an absence of a dose-response relationship. In fact, the number of SSEs increased in all four groups, including in the placebo group.
Basson R. Testosterone supplementation to improve women's sexual satisfaction: complexities and unknowns. Ann Intern Med. 2008;148:620-621.
Davis S, Papalia MA, Norman RJ, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med. 2008;148:569-577.
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More